Publications (4)22.71 Total impact

  • Source
    The Journal of allergy and clinical immunology 01/2013; 131(5). DOI:10.1016/j.jaci.2012.11.003 · 11.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: New requirements for the preparation and delivery of named patient products (NPPs) were introduced by the French authorities in February 2004. A working group composed of representatives of allergist and manufacturers, named “APSI”, was created. This group set up a decision-making process to establish a list of clinically relevant allergen extracts in line with these new requirements. This list was then submitted for validation to the French Drug Regulatory Agency (Agence française de sécurité sanitaire des produits de santé [Afssaps]). A list of 66 mother preparations was published by Afssaps in December 2007. This procedure guaranteed French allergists that the available allergen extracts are clinically relevant and that their quality is consistent with international recommendations, which benefits patients, the medical community and manufacturers. It is the first time in Europe that NPPs have been registered by governmental authorities. This action needs to go on.
    Revue Française d Allergologie 04/2010; 50(3):141-145. DOI:10.1016/j.reval.2010.02.013 · 0.22 Impact Factor
  • Journal of Allergy and Clinical Immunology 02/2010; 125(2). DOI:10.1016/j.jaci.2009.12.173 · 11.25 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine the prevalence of sensitization to lupin flour in patients consulting allergists, in order to evaluate the risk of primary and secondary allergies to lupin. A prospective study carried out by members of the Allergy Vigilance Network, using prick-tests with a commercial lupin flour extract in patients with various allergic symptoms. The study design classified patients into four groups: peanut allergy, current atopic disease, latent atopy, no atopy. Data were collected and analysed by Network coordinators. Over a two-month period, 88 French and Belgian allergists tested 5,366 patients: 2,680 children and 2,686 adults aged over 16 years. Of the 2,680 children, 11.15% presented with peanut allergy. The frequency of cross-reactivity with lupin was 17.1% for patients with peanut allergy, 2.5% for children with current atopic disease and 1.7% for healthy children with latent atopy. In the 2,686 adults, peanut allergy was diagnosed in 1.86% of patients with cross-reactivity to lupin in 14.6%. Sensitization to lupin was detected in 3.7% of patients with current atopic disease and in 1.8% of those with latent atopy. The relative frequency of latent sensitisation to lupin in patients of all ages presenting with atopic disease is a new factor indicating the likelihood of an increase in primary food allergies to lupin flour. This justifies the recent decision requiring mandatory labelling of lupin, and shows the need to inform consumers who may be unaware that this ingredient is being used increasingly. Sensitization to lupin should be searched by prick-tests in any case of peanut allergy. Prick-test to lupin may be valuable whenever a food allergy is suspected when no current food allergens have been identified.
    European annals of allergy and clinical immunology 03/2009; 41(1):17-22.